Инвега Drug photo

The description is actual on 26.07.2016

  • Latin name: Invega
  • ATH code: N05AX13
  • Active ingredient: Paliperidon (Paliperidone)
  • Producer: Alza Corporation (USA)


In 1 tablet of a paliperidon of 3, 6, 9 or 12 mg. Macrogoal, sodium chloride, povidone, gietelloza, stearic acid, butyl hydroxytoluene, ferrous oxide yellow and red, macrogoal, cellulose acetate, dye, wax of karnaubskiya as auxiliary components.

Release form

Tablets in a cover of the prolonged action of 3 mg, 6 mg, 9 mg and 12 mg.

Pharmacological action


Pharmacodynamics and pharmacokinetics


Antagonist dopamine D2 receptors and serotoninovy 5-HT2. Antipsychotic action is connected with blockade of D2 - dopamine receptors. In comparison with classical neuroleptics suppresses a physical activity less and provoke a katalepsy.

Eliminates negative and productive symptoms of schizophrenia, at the same time almost does not cause extrapyramidal side reactions. Exerts impact on a dream: reduces the period before backfilling, number of awakenings, increases duration and quality of a dream. Causes increase in level of prolactin in blood. Has moderate antiemetic effect.


At reception of one dose concentration of active ingredient increases in blood and reaches a maximum in a day. Equilibrium concentration are reached in 4–5 days of regular reception. Paliperidon — an active metabolite of a risperidon. Its features of release provide smaller fluctuations of concentration of a paliperidon.

It is quickly distributed in fabrics, for 74% contacts blood proteins. In a week after reception of one tablet of 59% it is allocated with urine. Is not exposed to a metabolism in a liver therefore it is allocated in not changed look. By the researches in vitro it is shown that isoenzymes of P450 cytochrome play a part in a metabolism, but not significant. An elimination half-life — 23 hours.

As active agent is not exposed to a metabolism in a liver, it is not necessary to reduce a dose at patients with moderate abnormal liver functions. However the dose has to be lowered at heavy renal failures. The pharmacokinetics of a paliperidon at teenagers is comparable with that at adults.

Indications to use

  • prevention of aggravations and treatment of schizophrenia at adult patients;
  • treatment of schizophrenia at teenagers;
  • schizoaffective frustration.


  • hypersensitivity;
  • pregnancy (only according to vital indications);
  • feeding period breast.

With care drug at convulsive states is appointed, dysphagies, senile dementia (cerebrovascular side effects are possible), Parkinson's illness in connection with risk of extrapyramidal frustration.

Side effects

Often found side reactions:

Infrequently found side reactions:

  • cystitis;
  • ear infections, bronchitis, sinusitis, tonsillitis;
  • anaphylactic reaction;
  • anemia, neutropenia, leukopenia;
  • giperprolaktinemiya;
  • anorexia, hypoglycemia and hyperglycemia;
  • diabetes mellitus;
  • sleep disorders, "dreadful" dreams;
  • spasms, disturbance of attention, paresthesia, psychomotor hyperactivity;
  • conjunctivitis, xerophthalmus, dacryagogue;
  • pain and ring in ears;
  • bradycardia, AV blockade, increase in an interval of QT, increase or decrease in the ABP;
  • meteorism, incontience calla, gastroenteritis;
  • arthralgia, swelling of a joint and constraint;
  • dysuria, urine incontience;
  • decrease in a libido, allocation from nipples, a gynecomastia,
  • sexual dysfunction, changes of a menstrual cycle;
  • peripheral hypostases, thirst, fever, hypothermia.

Invega, application instruction (Way and dosage)

Drug is accepted inside in the morning, irrespective of meal. The dosage of Invega depends on disease severity and age of patients.

At schizophrenia the adult appoint Invega of 6 mg of times a day. If increase of a dose is required it is recommended to increase it by 3 mg of times in 5 days. At some patients the effect comes at lower or high doses — in the range of 3-12 mg a day. Recommend to teenagers 3 mg a day. However also higher doses which increase carry out time in 5 days can be required.

At schizoaffective frustration the recommended dose makes 6 mg a day, in the morning. Increase in a dose up to 12 mg a day which is carried out gradually is also possible.

At a moderate abnormal liver function there is no need to reduce a dose. At heavy — a dose no more than 3 mg a day. At elderly patients the dose depends on function of kidneys. Safety of drug at treatment of schizophrenia at children till 12 flyings was not studied. At transfer of patients from a paliperidon on other neuroleptics it is necessary to watch a condition of the patient.


Overdose symptoms: drowsiness and excessive sedation, arterial hypotension, tachycardia, extrapyramidal disturbances and fibrillation of ventricles. Situation is aggravated as it is drug with the prolonged release of active agent. A symptomatic treatment with maintenance of adequate oxygenation, ventilation and function CCC. Heavy extrapyramidal symptoms are stopped to m-holinoblokatorami. There is no specific antidote.


To be careful at appointment with the HP extending QT interval. Paliperidon does not cause clinically significant interactions with HP which are metabolized by system of P450 cytochrome. In the researches in vitro it is shown what paliperidon does not cause oppression or induction of isoenzymes of this cytochrome.

Drug should be used with care in combinations with other medicines of the central action. It is impossible to appoint jointly with drugs which cause orthostatic hypotension. Neutralizes action of a levodopa. Interaction of this drug and lithium is a little probable.

Co-administration with sodium Valproatum — concentration of both drugs did not change. Significant interaction with paroksetiny is also noted. Use with risperidony was not studied, and with carbamazepine caused reduction of concentration of a paliperidon in blood for 37% in this connection it is necessary to adjust a dose of the last. Use with Trimethoprimum did not influence pharmacokinetic characteristics of a paliperidon.

Terms of sale

According to the recipe.

Storage conditions

Temperature is up to 25 °C.

Period of validity

2 years.


Coincidence on the ATH code of the 4th level:

Kseplion, Risperidon, Speridan, Rispolept.

About Invega

This medicine eliminates productive symptomatology (nonsense, hallucinations, an azhititation) at schizophrenia. On supervision of psychiatrists drug is more effective at the schizophrenia which is followed by an apatoabulichesky syndrome (indifference, indifference, detachment from everything, pathological lack of will, unwillingness to perform any operations). Administration of drug gives resotsializiruyushchy effect — apathy to all events vanishes and the potentiality to action appears. In the responses patients note efficiency of drug and existence of side effects.

  • "... Accepted two months on on 12 mg. Negative symptoms passed — became sociable, interest in life appeared. Very much prolactin raised and I was transferred to Rispolept".
  • "… The general state on Invege is much better, than on others. There was an aspiration to creativity which was gone 14 flyings ago and creative cheerfulness".
  • "… I accept 12 mg — the state was normalized, but to consolidate effect, one and a half told 1,5 more months to drink in this dosage, and then to lower to 9 mg".
  • "… From pobochek the most unpleasant at me — hormonal disturbances. Very much weight increases, absolutely were gone monthly, allocations from mammary glands and the breast grows".
  • "… I take medicine of Invega, I transfer well. The doctor told that the tablet cannot be divided as its cover provides gradual release and long effect of active ingredient".
  • "… At increase in a dose grippopodobny symptoms appear: an ache in joints, muscle pains, a nose congestion, thirst, hurried breathing — such state, as at a temperature over 40".

This drug is safer in comparison with risperidony, but is allowed for use only for adults and teenagers.


  • Invega of 3 mg No. 28 of a tablet of the prolonged action covered obolochkoyansen-Silag
  • Invega of 9 mg No. 28 of a tablet of the prolonged action covered obolochkoyansen-Silag
  • Invega of 6 mg No. 28 of a tablet of the prolonged action covered obolochkoyansen-Silag
to show still


  • Invega of a tablet of the prolonged action 6 mg No. 28silag (Switzerland)


  • Invega of the tab. pro-longum. deyst. 6 mg No. 28
Section: For a nervous system
in more detail

Education: Graduated from Sverdlovsk medical school (1968 - 1971) as "Paramedic". Graduated from the Donetsk medical institute (1975 - 1981) as "An epidemiologist, a hygienist". Passed postgraduate study in the Central scientific research institute of epidemiology Moscow (1986 - 1989). An academic degree – the candidate of medical sciences (degree is awarded in 1989, protection – the Central scientific research institute of epidemiology Moscow). Numerous advanced training courses are studied in epidemiology and infectious diseases.

Experience: Work as the manager of department of disinfection and sterilization of 1981 - 1992. Work as the manager of department of especially dangerous infections of 1992 - 2010. Teaching activity at Medical institute 2010 - 2013.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before use of medicine of Invega surely consult with the attending physician.